Letaplimab - Innovent Biologics
Alternative Names: IBI 188Latest Information Update: 28 Jun 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- No development reported Lymphoma; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In adolescents, In children, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (IV, Injection)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, First-line therapy, Newly diagnosed) in China (IV, Infusion)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, First-line therapy, Newly diagnosed) in USA (IV, Infusion)